1. The use of a polyvinylpyrrolidone with an average molecular weight of between 20 kd and 360 kd in a culture medium free of serum of animal origin, to increase the proliferation of adherent nonrecombinant animal or human cells subjected to an agitation flow of the medium.
2. The use as claimed in claim 1, in which the proliferation index of the cells in this medium is greater than 1.5.
3. The use of a polyvinylpyrrolidone with an average molecular weight of between 20 kd and 360 kd in a culture medium free of serum of animal origin, to promote the adhesion of adherent animal or human cells subjected to an agitation flow of the medium.
4. The use of a polyvinylpyrrolidone with an average molecular weight of between 20 kd and 360 kd in a culture medium free of serum of animal origin, to reduce the death rate of adherent animal or human cells subjected to an agitation flow of the medium.
5. The use as claimed in any one of claims 1 to 4, in which the polyvinylpyrrolidone is noncrosslinked.
6. The use as claimed in any one of claims 1 to 5, in which the polyvinylpyrrolidone has an average molecular weight of 40 kd.
7. The use as claimed in any one of claims 1 to 6, in which the percentage of polyvinylpyrrolidone in the culture medium is between 0.01% and 2%.
8. The use as claimed in claim 7, in which the percentage of polyvinylpyrrolidone in the culture medium is 0.1%.
9. The use as claimed in any one of claims 1 to 8, in which the culture medium has a chemically defined composition.
10. The use as claimed in one of claims 1 to 9, for the production of nonrecombinant adherent human or animal cells in batch or feed batch mode or in continuous culture mode.
11. A process for producing adherent nonrecombinant animal or human cells, comprising:
(i) a first step in which a suspension of cells in a serum-free culture medium containing a polyvinylpyrrolidone with an average molecular weight of between 20 kd and 360 kd is inoculated in a culturing device comprising an adhesion support;
(ii) a second step in which the cells multiply under agitation in the same culture medium;
(iii) a third step in which the cells are harvested when they have reached a growth stage.
12. The process as claimed in claim 11, in which the polyvinylpyrrolidone has an average molecular weight of 40 kd.
13. The process as claimed in claim 11 or 12, in which the percentage of polyvinylpyrrolidone in the culture medium is between 0.01% and 2%.
14. The process as claimed in one of claims 11 to 13, in which the percentage of polyvinylpyrrolidone in the culture medium is 0.1%.
15. The process as claimed in one of claims 11 to 14, in which the adhesion support consists of microcarriers.
16. The process as claimed in claim 15, in which the microcarriers consist of a dextran matrix (cytodex 1).
17. The process as claimed in one of claims 11 to 16, in which the culturing device is a biogenerator.
18. The process as claimed in one of claims 11 to 17, in which the culture mode is the batch or feed batch mode or the continuous culture mode.
19. Process as claimed in one of claims 11 to 18, in which the cells are cells of the Vero or MRC5 line.
20. A process for producing viruses, according to which:
(i) cells are infected with viruses in a first culture medium;
(ii) the viruses are left to propagate and are harvested in a second culture medium;
at least one of the two media being a medium free of serum of animal origin and containing a polyvinylpyrrolidone with an average molecular weight of beween 20 kd and 360 kd.
21. The process as claimed in claim 20, in which the first culture medium is free of serum of animal origin and contains a polyvinylpyrrolidone with an average molecular weight of between 20 kd and 360 kd.
22. The process as claimed in claim 20 or 21, in which the second culture medium is free of serum of animal origin and contains a polyvinylpyrrolidone with an average molecular weight of between 20 kd and 360 kd.
23. The process as claimed in one of claims 20 to 22, in which the viruses are produced from cells of the Vero or MRC5 line.
24. The process as claimed in claim 23, in which the viruses produced are polio virus, rabies virus, hepatitis A virus or rubella virus.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A computer-implemented method comprising:
(A) decoding a first portion of an audio signal into a first word in a token stream;
(B) after (A), inserting a punctuation mark into the token stream at a position after the first word; and
(C) after (B), decoding a second portion of the audio signal into a second word in the token stream at a position after the punctuation mark.